European Medical Affairs Teams Performance in Multiple Sclerosis Sector Investigated by FirstWord in Its Report Available at MarketPublishers.24 Aug 2015 • by Natalie Aster
LONDON – Market Publishers Ltd announces that a research report on the medical affairs reputations in the multiple sclerosis market in the EU5 has been recently uploaded to its catalogue.
What is the current status of the interactions with different medical affairs teams that deal with multiple sclerosis? Are physicians satisfied with the performance of medical affairs teams in the EU5? Are there any ways, in which physicians would like to cooperate with medical affairs experts? What are the less effective and the most effective drugs used in the multiple sclerosis treatment? How the quality of life of multiple sclerosis patients can be improved? Do all the services provided by medical affair teams satisfy the physicians’ needs? Why is it important for physicians to get regular, accurate, unbiased scientific and drug information? How well your team stacks up against the competition? Where work is still needed? Which MA teams do physicians rate the best or worst for the products surveyed? How physicians use the services of Medical Affairs teams?
The answer to these and other questions can be easily found in the topical research report “Medical Affairs Reputations (EU5): Multiple Sclerosis” elaborated by FirstWord, an expert in the global healthcare.
Medical Affairs Reputations (EU5): Multiple Sclerosis
Date: July, 2015
Price: US$ 6,900.00
This in-demand research study offers an insightful overview of the EU5 multiple sclerosis sector scenario, providing the appraisal of the current status of interactions with different medical affairs teams in the region. The report presents a comprehensive assessment of the competitive landscape and also includes a competitive evaluation of medical affairs teams’ performance on various attributes. It contains a comparative analysis of the products used for treatment of multiple sclerosis in the EU5. Moreover, the report gives a comprehensive examination of the performance of the European and US medical affairs teams that are active in the multiple sclerosis market. In addition, areas where the medical affair teams are demonstrating a solid performance are also highlighted in the report. An exhaustive insight into the improvements to be done in the multiple sclerosis sector are also reviewed.
Products Covered in Report Include: Bayer, Betaseron (Interferon-beta-1b), Biogen, Avonex (Interferon-beta-1a), Tecfidera (Dimethyl Fumarate), Tysabri (Natalizumab), Merck Serono, Rebif (Interferon-beta-1a)/BulletPoint>, Novartis, Extavia (Interferon-beta-1b), Gilenya (Fingolimod), Sanofi, Aubagio (Teriflunomide), Teva and Copaxone (Glatiramer acetate).
Other topical research reports by the publisher can be found at FirstWord page.